Caution! It’s Not Safe to Jump on the SAVA Stock Hype Train.
Caution! It’s Not Safe to Jump on the SAVA Stock Hype Train.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股票市场新闻、股票建议和交易提示
There's been some drama surrounding $Cassava Sciences (SAVA.US)$ recently. First, there was a report stating that the Securities and Exchange Commission, or SEC, cleared Cassava Sciences of charges of manipulating research results. Not long afterward, however, Cassava disputed the legitimacy of that report. These twists and turns in the ongoing story make it difficult to recommend SAVA stock with confidence now.
周围发生了一些戏剧性的事情$Cassava Sciences (SAVA.US)$最近。首先，有报道称，美国证券交易委员会(简称美国证券交易委员会)澄清了木薯科学公司操纵研究结果的指控。然而，不久之后，卡萨瓦对这份报告的合法性提出了质疑。正在进行的故事中的这些曲折使得现在很难有信心地推荐Sava股票。
Let's start with the basics. Cassava Sciences is a biotechnology firm with a primary product known as Simufilam. It's a clinical-stage Alzheimer's treatment that targets a protein called filamin A.
让我们从基础知识开始吧。木薯科学公司是一家生物技术公司，其主要产品是Simufilam。这是一种临床阶段的阿尔茨海默氏症治疗方法，针对的是一种名为细丝素A的蛋白质。
Simufilam is experimental – and controversial. So, let's see if we can sort out the facts from the speculation, and decide whether SAVA stock is safe to invest in now.
Simufilam是试验性的，也是有争议的。那么，让我们看看我们是否能从投机中理清事实，并决定现在投资Sava股票是否安全。
SAVA Cassava Sciences $45.09
Sava木薯科学 $45.09
A Roller-Coaster Ride with SAVA Stock
萨瓦股票的过山车之旅
Biotechnology stocks are known for fast price action. Indeed, Cassava Sciences' investors have been on a veritable roller-coaster ride with thrills but also plenty of spills.
生物技术股以快速的价格走势而闻名。事实上，木薯科学的投资者经历了一场名副其实的过山车之旅，既有刺激，也有大量的泄漏。
We're giving SAVA stock a "C" rating because there's too much confusion going to fully endorse or deprecate it. Let's see what we can sort out, though.
我们给Sava的股票评级为C，因为要完全支持还是反对它，还有太多的困惑。不过，让我们看看我们能解决什么问题。
For all intents and purposes, the hubbub started in November of last year. That's when the Wall Street Journal reported that the SEC was investigating Cassava Sciences for allegedly manipulating Simufilam research results.
无论出于何种意图和目的，这场喧嚣始于去年11月。就在那时，《华尔街日报》报道称，美国证券交易委员会正在调查木薯科学公司涉嫌操纵西穆菲拉姆的研究结果。
Cassava Sciences CEO Remi Barbier strenuously denied the allegation. "There is zero evidence, zero credible evidence, zero proof that I've ever engaged in, nor anyone I know, has ever engaged in funny business," Barbier asserted.
木薯科学公司首席执行官雷米·巴比尔极力否认这一指控。“没有任何证据，没有可信的证据，没有证据证明我曾经从事过，我认识的任何人都没有从事过滑稽的生意，”巴比尔断言。
Cassava Science Disputes an SEC Clearance Report
木薯科学驳斥美国证券交易委员会清查报告
SAVA stock lost a lot of its value since November of 2021. The roller-coaster ride was only just beginning, however.
自2021年11月以来，Sava的股票贬值了很多。然而，这场过山车之旅才刚刚开始。
Fast-forward to last week, when a report emerged claiming that the SEC "has officially closed its case" against Cassava Sciences. The report displayed what appeared to be an image of a letter from the SEC, stating that the agency is "withholding" a "case closing recommendation."
快进到上周，一份报告浮出水面，声称美国证券交易委员会对木薯科学公司的诉讼已正式结案。这份报告展示了一张图片，似乎是美国证券交易委员会的一封信，声明该机构“拒绝”一项“结案建议”。
Is it possible that "withholding" meant that the SEC is currently not clearing Cassava's case? Perhaps it's possible, since soon afterward, Cassava Science apparently denied knowing about any such SEC clearance.
有没有可能是说，美国证券交易委员会目前不卡萨瓦的案子了结了？也许这是可能的，因为不久之后，木薯科学显然否认知道任何这样的美国证券交易委员会许可。
"The company is unable to establish the legitimacy of communications circulating on mass media, or elsewhere, purportedly sent from one such government agency following a request for public access to private records made under the Freedom of Information Act," the company said in an SEC filing.
新浪美国证券交易委员会在一份提交给新浪美国证券交易委员会的文件中表示，“公司无法确定大众媒体或其他地方传播的信息的合法性，这些信息据称是在根据《信息自由法》提出公开获取私人记录的请求后由这样的政府机构发出的。”
With all of these head-turning events, SAVA stock flipped from around $30 to $50 and then down to $40 last week. It's enough to make cautious investors stay out of the trade, at least for the time being.
在所有这些引人注目的事件中，Sava的股价从30美元左右跌至50美元，然后在上周跌至40美元。这足以让谨慎的投资者远离这笔交易，至少目前是这样。
What You Can Do Now
你现在能做什么
Until the dust settles and questions surrounding the SEC probe are cleared up, you don't have to take a stance on Cassava Sciences. Sometimes, it just makes sense to stay on the sidelines.
在尘埃落定，围绕美国证券交易委员会调查的问题得到澄清之前，你不必对木薯科学采取立场。有时候，袖手旁观是有意义的。
Besides, SAVA stock has been volatile lately, and that's not everyone's cup of tea. So, feel free to watch and wonder without having to place a trade now.
此外，Sava的股票最近一直在波动，这并不是每个人都喜欢的。因此，现在不必进行交易，就可以自由地观看和好奇。
On the date of publication, neither Louis Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
在文章发表之日，Louis Navellier和主要负责本文的InvestorPlace Research工作人员都没有(直接或间接)持有本文提到的证券的任何头寸。
Louis Navellier, who has been called "one of the most important money managers of our time," has broken the silence in this shocking "tell all" video… exposing one of the most shocking events in our country's history… and the one move every American needs to make today.
路易·纳维利耶，被称为“我们这个时代最重要的基金经理之一”，在这段令人震惊的“告诉所有人”的视频…中打破了沉默揭露了我国历史上最令人震惊的事件之一…这也是今天每个美国人都需要采取的行动。
The post Caution! It's Not Safe to Jump on the SAVA Stock Hype Train. appeared first on InvestorPlace.
邮报警告！跳上萨瓦股票炒作列车是不安全的。最先出现在InvestorPlace上。